^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             39    10631001 10631002 10631003    
                           11601002 11601006 11601007    
                           13031001 13031004 13581001    
                           13581010 13581014 13991001    
                           13991002 13991004 13991007    
                           13991009 13991010 16591001    
                           16591003 16591006 17601002    
                           17601003 17601005 17601007    
                           17601012 17601014 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731004 19731006 19831001    
                           19831005 19831008 19901003    
      AVISITN         4    1 4 8 12                      
      trtn            3    1 2 3                         
      SSNRISN         2    1 2                           
      AGEGR2N         2    1 2                           
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      wk12            2    0 1                           


                          Dimensions

              Covariance Parameters            10
              Columns in X                     39
              Columns in Z                      0
              Subjects                         39
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read             129
          Number of Observations Used             129
          Number of Observations Not Used           0
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       307.31389643                
          1              4       259.26628064      0.01792944
          2              1       258.74878054      0.00170527
          3              1       258.70397960      0.00002075
          4              1       258.70346486      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.5533
                UN(2,1)     id           0.3273
                UN(2,2)     id           0.6855
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(3,1)     id           0.2904
                UN(3,2)     id           0.6051
                UN(3,3)     id           0.9982
                UN(4,1)     id           0.3779
                UN(4,2)     id           0.3500
                UN(4,3)     id           0.5752
                UN(4,4)     id           0.6918


                        Fit Statistics

             -2 Res Log Likelihood           258.7
             AIC (Smaller is Better)         278.7
             AICC (Smaller is Better)        280.8
             BIC (Smaller is Better)         295.3
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         48.61          <.0001


                 Type 3 Tests of Fixed Effects
 
                           Num     Den
     Effect                 DF      DF    F Value    Pr > F

     BASE                    1    28.5      34.57    <.0001
     trtn                    2    26.8       0.09    0.9100
     wk12                    1    19.3       4.40    0.0494
     SSNRISN                 1    27.9       1.71    0.2022
     BASE*wk12               1    18.8       1.93    0.1815
     trtn*AGEGR2N            2    26.7       0.09    0.9185
     trtn*wk12               2    20.1       0.78    0.4702
     AGEGR2N*wk12            1    20.3       0.03    0.8548
     trtn*AGEGR2N*wk12       2    20.1       1.13    0.3430
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                     Pooled
                     Age
                     Group             Standard
 Effect        trtn  2 (N)   Estimate     Error    DF  t Value

 trtn*AGEGR2N  1     1        -0.8311    0.3860  23.3    -2.15
 trtn*AGEGR2N  1     2        -0.5336    0.3620  28.3    -1.47
 trtn*AGEGR2N  2     1        -0.7128    0.2503  25.1    -2.85
 trtn*AGEGR2N  2     2        -0.3598    0.4077  31.9    -0.88
 trtn*AGEGR2N  3     1        -0.6445    0.2774  27.4    -2.32
 trtn*AGEGR2N  3     2        -0.5361    0.3921  28.6    -1.37

 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                    Pooled
                    Age
                    Group
Effect        trtn  2 (N)   Pr > |t|   Alpha     Lower     Upper

trtn*AGEGR2N  1     1         0.0419    0.05   -1.6291  -0.03307
trtn*AGEGR2N  1     2         0.1515    0.05   -1.2748    0.2075
trtn*AGEGR2N  2     1         0.0087    0.05   -1.2282   -0.1975
trtn*AGEGR2N  2     2         0.3841    0.05   -1.1903    0.4708
trtn*AGEGR2N  3     1         0.0278    0.05   -1.2133  -0.07569
trtn*AGEGR2N  3     2         0.1822    0.05   -1.3385    0.2663
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              23    10631001 10631002 10631003    
                            11601002 11601006 11601007    
                            13031001 13581001 13581010    
                            13581014 13991002 13991004    
                            13991007 13991009 16591001    
                            17601005 17601007 17601014    
                            17661004 19731002 19731006    
                            19831001 19901003             
      AVISITN          4    1 4 8 12                      
      SSNRISN1         2    0 1                           


                          Dimensions

              Covariance Parameters            10
              Columns in X                     12
              Columns in Z                      0
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Subjects                         23
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read              76
          Number of Observations Used              76
          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       193.52964994                
          1              3       157.19647993      0.01631851
          2              1       156.84493048      0.00119330
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          3              1       156.82132720      0.00001141
          4              1       156.82111248      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.6187
                UN(2,1)     id           0.4301
                UN(2,2)     id           0.9840
                UN(3,1)     id           0.4815
                UN(3,2)     id           0.9778
                UN(3,3)     id           1.4719
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(4,1)     id           0.5123
                UN(4,2)     id           0.5621
                UN(4,3)     id           0.7914
                UN(4,4)     id           0.7650


                        Fit Statistics

             -2 Res Log Likelihood           156.8
             AIC (Smaller is Better)         176.8
             AICC (Smaller is Better)        180.9
             BIC (Smaller is Better)         188.2


 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         36.71          <.0001


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1    16.9      17.14    0.0007
    trtn1                     1    16.7       0.03    0.8719
    wk12                      1    11.1       2.91    0.1158
    SSNRISN1                  1    16.1       1.52    0.2356
    AGEGR2N1                  1    17.2       0.12    0.7325
    BASE*wk12                 1    11.1       1.32    0.2742
    trtn1*AGEGR2N1            1    16.5       1.14    0.3009
    trtn1*wk12                1    11.1       0.03    0.8689
    wk12*AGEGR2N1             1    11.1       2.51    0.1408
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    trtn1*wk12*AGEGR2N1       1      11       2.13    0.1722


                           Estimates
 
                              Standard
Label               Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO  Week 4    -0.7192    0.5218  16.2    -1.38    0.1868
2 ACT-PBO  Week 4    0.08993    0.5492  16.7     0.16    0.8719
1 ACT-PBO  Week 12   0.02500    0.5780  12.1     0.04    0.9662
2 ACT-PBO  Week 12   0.01201    0.6700  14.2     0.02    0.9859

 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
       Label                Alpha       Lower       Upper

       1 ACT-PBO  Week 4     0.05     -1.8241      0.3857
       2 ACT-PBO  Week 4     0.05     -1.0701      1.2499
       1 ACT-PBO  Week 12    0.05     -1.2329      1.2829
       2 ACT-PBO  Week 12    0.05     -1.4232      1.4472


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1   16.5      1.14
 Treatment*Week 12*Subgroup Interaction      1     13      0.00

 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.3009
        Treatment*Week 12*Subgroup Interaction   0.9884
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              30    10631001 10631003 11601002    
                            11601006 13031001 13031004    
                            13581001 13581010 13581014    
                            13991001 13991010 16591003    
                            16591006 17601002 17601003    
                            17601007 17601012 17601025    
                            17661002 17661004 17661006    
                            19691001 19731001 19731002    
                            19731004 19731006 19831001    
                            19831005 19831008 19901003    
      AVISITN          4    1 4 8 12                      
      SSNRISN1         2    0 1                           


 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Covariance Parameters            10
              Columns in X                     12
              Columns in Z                      0
              Subjects                         30
              Max Obs per Subject               4


                    Number of Observations

          Number of Observations Read              96
          Number of Observations Used              96
          Number of Observations Not Used           0


 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       232.86270761                
          1              2       195.49547923      0.03523280
          2              1       194.68410544      0.00421214
          3              1       194.59547523      0.00011523
          4              1       194.59321755      0.00000012
          5              1       194.59321520      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           0.5690
                UN(2,1)     id           0.3635
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(2,2)     id           0.7066
                UN(3,1)     id           0.4031
                UN(3,2)     id           0.6439
                UN(3,3)     id           1.1283
                UN(4,1)     id           0.4961
                UN(4,2)     id           0.4811
                UN(4,3)     id           0.8772
                UN(4,4)     id           1.0010


                        Fit Statistics

             -2 Res Log Likelihood           194.6
             AIC (Smaller is Better)         214.6
             AICC (Smaller is Better)        217.6
             BIC (Smaller is Better)         228.6
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   9         38.27          <.0001


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    BASE                      1    23.2      33.11    <.0001
    trtn2                     1    23.7       0.42    0.5212
    wk12                      1    13.1       7.74    0.0155
    SSNRISN1                  1    21.7       0.56    0.4607
    AGEGR2N1                  1      24       0.21    0.6518
    BASE*wk12                 1    13.2       5.29    0.0383
    trtn2*AGEGR2N1            1    23.6       1.06    0.3146
    trtn2*wk12                1    16.3       1.11    0.3082
    wk12*AGEGR2N1             1    12.7       2.32    0.1520
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
    Effect                   DF      DF    F Value    Pr > F

    trtn2*wk12*AGEGR2N1       1    15.6       3.44    0.0828


                           Estimates
 
                               Standard
Label                Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO    Week 4   -0.3088    0.3640  22.9    -0.85    0.4051
2 ACT-PBO  Week 4      0.3241    0.4978  23.7     0.65    0.5212
1 ACT-PBO  Week 12     0.3090    0.4708  15.1     0.66    0.5215
2 ACT-PBO  Week 12    -0.3029    0.7705  20.4    -0.39    0.6983

 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
      Label                 Alpha       Lower       Upper

      1 ACT-PBO    Week 4    0.05     -1.0620      0.4444
      2 ACT-PBO  Week 4      0.05     -0.7039      1.3522
      1 ACT-PBO  Week 12     0.05     -0.6938      1.3118
      2 ACT-PBO  Week 12     0.05     -1.9083      1.3025


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1   23.6      1.06
 Treatment*Week 12*Subgroup Interaction      1   19.2      0.46

 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.3146
        Treatment*Week 12*Subgroup Interaction   0.5080
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
